Delivery Order SPE2DB25D3022-SPE2DB25FWCBY
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,538.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on August 4, 2025. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 5, 2025, and represents a direct pharmaceutical procurement to support federal healthcare needs. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,390.75 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 ml pen injections on August 1, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed price delivery order with an ultimate completion date of August 4, 2025. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency (DLA) awarded a $1,172.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract represents a single delivery order fulfilling federal pharmaceutical procurement needs for military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $3,939.78 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pens on July 28, 2025, with completion scheduled for July 29, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply portfolio. The product will be delivered to the company's location in Conshohocken,...
- The Defense Logistics Agency awarded a $34,076.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injectors. This non-competitive, non-set-aside delivery order is scheduled for ultimate completion on July 29, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role as a pharmaceutical...
- The Defense Logistics Agency has awarded a delivery order valued at $4,397.68 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL quantities. This firm fixed-price contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a non-competitive, competitively-awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.48 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pre-filled pens. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and...
- The Defense Logistics Agency awarded a $14,089.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. The award was competitively procured with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB25D3022Indefinite Delivery Contract
- SPE2DB25D3022-SPE2DB25FWCBYDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,500.82 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on July 30, 2025. This firm fixed-price delivery order, which represents a non-set-aside competitive award, is scheduled for completion by July 31, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract involves the supply of a diabetes and weight management medication in injectable pen format to support federal medical procurement requirements. This delivery order falls under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal military and veteran healthcare systems, supplying an extensive portfolio of pharmaceutical products and medical supplies. The company's continued selection for such awards demonstrates its capability to meet competitive federal procurement standards and support the Defense Health Agency's healthcare supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 7/30/25 |